Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Unexpected Renal Toxicity

Autor:	Olatoyosi Odenike, Lucy A. Godley, Richard A. Larson, Andrew S. Artz, Lisa Pape, Kate Swanson, Linda Schroeder, Wendy Stock, P. Del Cerro, Sarah Horowitz, Amittha Wickrema, Elizabeth Rich, Scott Allen, K. van Besien, Justin Kline
Rok vydání:	2009
Předmět:	Oncology Melphalan medicine.medical_specialty Transplantation Hematopoietic cell business.industry chemical and pharmacologic phenomena Hematology Phase i ii Internal medicine Toxicity medicine Alemtuzumab Clofarabine In patient business medicine.drug
Zdroj:	Biology of Blood and Marrow Transplantation. 15(2)
ISSN:	1083-8791
DOI:	10.1016/j.bbmt.2008.12.324
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b568ee27c6811f684351b149946f4d42 Zobrazit plný text záznamu Full Text from ScienceDirect